Second trimester two-step trisomy 18 screening using maternal serum markers. 2002

Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France. francoise.muller@apr.ap-hop-paris.fr

Trisomy 21 maternal serum marker screening has led to screening for other anomalies, including trisomy 18. Trisomy 18 is generally prenatally diagnosed because of major morphological defects. However, in up to 30% of cases ultrasound signs are unclear, and in most cases diagnosis is performed late in pregnancy. Of the different maternal serum markers, PAPP-A is now considered as the best for trisomy 18 screening. However, pregnancy-associated plasma protein A (PAPP-A) is of value in first trimester screening for trisomy 21, but not in the second trimester. We therefore propose a two-step screening strategy. Based on 45 trisomy 18 cases, we confirm the values of alpha-fetoprotein (AFP) (median 0.61 MoM), free beta-human chorionic gonadotrophin (beta-hCG) (median 0.24 MoM) and of PAPP-A (median 0.08 MoM). In the first step, a 0.5 MoM cut-off for AFP or for free beta-hCG resulted in detection of 37/45 trisomy 18 cases (82%) with a 10% false-positive rate. The second step consisted of the measurement of PAPP-A for all these false-positive cases. Using a PAPP-A cut-off of 0.5 MoM, all the 37 trisomy 18 cases were detected, but now with a 0.1-0.2% false-positive rate. Amniocentesis was only offered to these few patients. This two-step second trimester screening will be of value for patients who have not been included in first trimester screening based on nuchal translucency (NT) measurement combined with the first trimester markers, PAPP-A and free beta-hCG.

UI MeSH Term Description Entries
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D011266 Pregnancy-Associated Plasma Protein-A A product of the PLACENTA, and DECIDUA, secreted into the maternal circulation during PREGNANCY. It has been identified as an IGF binding protein (IGFBP)-4 protease that proteolyzes IGFBP-4 and thus increases IGF bioavailability. It is found also in human FIBROBLASTS, ovarian FOLLICULAR FLUID, and GRANULOSA CELLS. The enzyme is a heterotetramer of about 500-kDa. PAPP-A,IGFBP-4 Metalloproteinase,IGFBP-4 Protease,IGFBP-4-Specific Proteinase,Insulin-Like Growth Factor-Dependent IGF Binding Protein-4 Protease,Insulin-Like-Growth Factor Binding Protein-4 Protease,PAPP-alpha,Pregnancy Associated alpha Plasma Protein,Pregnancy-Associated alpha-Plasma Protein,IGFBP 4 Metalloproteinase,IGFBP 4 Protease,Insulin Like Growth Factor Binding Protein 4 Protease,Insulin Like Growth Factor Dependent IGF Binding Protein 4 Protease,Metalloproteinase, IGFBP-4,PAPP alpha,Pregnancy Associated Plasma Protein A,Protease, IGFBP-4
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D002887 Chromosomes, Human, Pair 18 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 18
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
March 2003, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
June 2013, Journal of medical screening,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
January 2020, Frontiers in genetics,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
June 2012, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
June 2003, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
September 1998, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
October 1999, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
August 1990, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
October 2005, Prenatal diagnosis,
Françoise Muller, and Corinne Sault, and Catherine Lemay, and Nathalie Roussel-Mizon, and François Forestier, and Jean-Louis Frendo, and
July 1994, Prenatal diagnosis,
Copied contents to your clipboard!